QGEN - QIAGEN N.V.
| Previous Close | 39.77 |
| Open | 40.25 |
| Bid | 40.22 x 1000 |
| Ask | 40.23 x 1000 |
| Day's Range | 40.11 - 40.35 |
| 52 Week Range | 31.10 - 40.42 |
| Volume | 241,617 |
| Avg. Volume | 1,355,008 |
| Market Cap | 9.072B |
| Beta (3Y Monthly) | 0.92 |
| PE Ratio (TTM) | 49.06 |
| EPS (TTM) | 0.82 |
| Earnings Date | May 1, 2019 - May 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.80 |
- Markit•3 hours ago
See what the IHS Markit Score report has to say about Qiagen NV.
Qiagen NV NYSE:QGENView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for QGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold QGEN had net inflows of $766 million over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Business Wire•2 days ago
QIAGEN supports World TB Day with major innovations in the fight against latent tuberculosis
Developing new automation options for QuantiFERON®-TB Gold Plus – the modern blood-based test for TB detection – and new QFT Access for high burden, low-resource regions
- Zacks•6 days ago
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
- Simply Wall St.•9 days ago
Is QIAGEN N.V.’s (NYSE:QGEN) Balance Sheet A Threat To Its Future?
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like QIAGEN N.V. (NYSE:QGEN), with a market cap of US$9.0b, are often out of the spotlight.Read More...
Motley Fool•14 days agoNatera Inc (NTRA) Q4 2018 Earnings Conference Call Transcript
NTRA earnings call for the period ending December 31, 2018.
- Zacks•14 days ago
QIAGEN Partners With Tecan to Advance QFT-Plus Diagnostic Test
QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.
- Business Wire•18 days ago
QIAGEN and Tecan Announce Collaboration to Streamline Preanalytical Processing of QuantiFERON-TB Gold Plus
Non-exclusive collaboration aims to accelerate adoption and ease of use in processing single-tube sample collection version of the market-leading modern blood test for latent TB de
- Zacks•20 days ago
Why Is Qiagen (QGEN) Up 8.1% Since Last Earnings Report?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire•20 days ago
QIAGEN Announces 20-F Annual Report Filing for 2018 Results
QIAGEN N.V. announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2018, with the U.S.
- Simply Wall St.•27 days ago
QIAGEN N.V. (NYSE:QGEN): Are Analysts Bullish?
In December 2018, QIAGEN N.V. (NYSE:QGEN) announced its most recent earnings update, which indicated that the business experienced a major tailwind, more than doubling its earnings from the prior year.Read More...
- Zacks•last month
Intuitive Surgical Gets FDA Nod for Ion Endoluminal System
The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.
- Business Wire•last month
QIAGEN partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens
Frankfurt Prime Standard: QIA) today announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V. (CURE.NX), to develop innovative bioinformatics and assay solutions to accelerate research targeting the growing global health challenges posed by antibiotic-resistant bacteria. QIAGEN has acquired an exclusive license to leverage Ares Genetics’ proprietary antimicrobial resistance database, ARESdb, as well as bioinformatics tools and workflows from the ARES Technology Platform, AREStools, in QIAGEN’s bioinformatics products and services for researchers.
- Zacks•last month
Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y
Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.
- Motley Fool•last month
The $100 Billion Investing Opportunity That Could Revolutionize Cancer Treatment
This exciting area of cancer research could turn into a huge industry. How can investors potentially profit?
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of QGEN earnings conference call or presentation 5-Feb-19 2:00pm GMT
Q4 2018 Qiagen NV Earnings Call
- Motley Fool•2 months ago
QIAGEN Continues to Transform
With new products, growth at the diagnostic test company is set to accelerate this year.
- Simply Wall St.•2 months ago
What Kind Of Shareholders Own QIAGEN N.V. (NYSE:QGEN)?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in QIAGEN N.V.Read More...
Motley Fool•2 months agoQiagen N.V. (QGEN) Q4 2018 Earnings Conference Call Transcript
QGEN earnings call for the period ending December 31, 2018.
- Zacks•2 months ago
QIAGEN's (QGEN) Q4 Earnings In Line, Revenues Miss Mark
QIAGEN's (QGEN) suffers sluggish sales at Americas. However, the company delivers strong global growth.
- Zacks•2 months ago
Qiagen (QGEN) Q4 Earnings Meet Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 0.00% and -1.43%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Qiagen: 4Q Earnings Snapshot
The Venlo, Netherlands-based company said it had profit of 26 cents per share. Earnings, adjusted for amortization costs and non-recurring costs, came to 40 cents per share. The results met Wall Street ...
